KR20100134680A - 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체 - Google Patents

스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체 Download PDF

Info

Publication number
KR20100134680A
KR20100134680A KR1020107023415A KR20107023415A KR20100134680A KR 20100134680 A KR20100134680 A KR 20100134680A KR 1020107023415 A KR1020107023415 A KR 1020107023415A KR 20107023415 A KR20107023415 A KR 20107023415A KR 20100134680 A KR20100134680 A KR 20100134680A
Authority
KR
South Korea
Prior art keywords
oxo
ethyl
piperidin
carboxylic acid
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107023415A
Other languages
English (en)
Korean (ko)
Inventor
알렉산더 비스쵸프
쿠마 선다레산
피. 바라 코테스와라 라오
바라티라자 아이난
하리하라수브라마니안 아얌페루말
기리쉬 에이 알
스리니바스 타티파르티
가네쉬 프라브후
호사할리 서브라만야
Original Assignee
포레스트 래보러토리즈 홀딩스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포레스트 래보러토리즈 홀딩스 리미티드 filed Critical 포레스트 래보러토리즈 홀딩스 리미티드
Publication of KR20100134680A publication Critical patent/KR20100134680A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
KR1020107023415A 2008-03-20 2009-03-20 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체 Ceased KR20100134680A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN575KO2008 2008-03-20
IN575/KOL/2008 2008-03-20
US4948008P 2008-05-01 2008-05-01
US61/049,480 2008-05-01

Publications (1)

Publication Number Publication Date
KR20100134680A true KR20100134680A (ko) 2010-12-23

Family

ID=41089526

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107023415A Ceased KR20100134680A (ko) 2008-03-20 2009-03-20 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체

Country Status (14)

Country Link
US (1) US8129376B2 (https=)
EP (1) EP2268143A4 (https=)
JP (1) JP2011518774A (https=)
KR (1) KR20100134680A (https=)
CN (1) CN102036558A (https=)
AU (1) AU2009225441B2 (https=)
BR (1) BRPI0909183A2 (https=)
CA (1) CA2719000A1 (https=)
IL (1) IL208232A0 (https=)
MX (1) MX2010010241A (https=)
NZ (1) NZ588633A (https=)
RU (1) RU2010142937A (https=)
WO (1) WO2009117676A2 (https=)
ZA (1) ZA201007252B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8642583B2 (en) * 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
WO2012007500A2 (de) 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
DK2707101T3 (da) 2011-05-12 2019-05-13 Proteostasis Therapeutics Inc Proteostaseregulatorer
NO2686520T3 (https=) 2011-06-06 2018-03-17
FR3000491B1 (fr) * 2012-09-27 2015-08-28 Univ Lille Ii Droit & Sante Composes utilisables dans le traitement des infections mycobacteriennes
CN103772267A (zh) * 2012-10-24 2014-05-07 常州化学研究所 一种二苯胺制备咔唑的方法
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
UA118034C2 (uk) * 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
CN107205972A (zh) * 2014-04-23 2017-09-26 X-Rx股份有限公司 自分泌运动因子的取代的n‑(2‑(氨基)‑2‑氧代乙基)苯甲酰胺抑制剂及它们的制备和在治疗lpa‑依赖的或lpa‑介导的疾病中的用途
US20160047307A1 (en) * 2014-08-15 2016-02-18 General Electric Company Power train architectures with low-loss lubricant bearings and low-density materials
WO2016054560A1 (en) 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
ES2973850T3 (es) 2016-09-20 2024-06-24 Centre Leon Berard Derivados del benzoimidazol como agentes anticancerígenos
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
CN107663184A (zh) * 2017-11-15 2018-02-06 上海皓伯化工科技有限公司 一种N‑Boc‑4‑羟基哌啶的合成方法
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
WO2019209962A1 (en) 2018-04-25 2019-10-31 Yumanity Therapeutics, Inc. Compounds and uses thereof
EP3790863A1 (en) 2018-05-09 2021-03-17 Akebia Therapeutics Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
MX2021008903A (es) * 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EP4027994A4 (en) * 2019-09-13 2024-03-27 Dana-Farber Cancer Institute, Inc. KDM INHIBITORS AND THEIR USES
CN110845396B (zh) * 2019-11-07 2023-01-20 宿迁联盛科技股份有限公司 一种2,2,6,6-四甲基-4-哌啶胺类化合物的制备方法
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN117247347A (zh) * 2023-09-15 2023-12-19 安徽昊帆生物有限公司 N-Boc-4-氨基哌啶的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6659090A (en) 1989-11-16 1991-06-13 Warner-Lambert Company Acat inhibitors
US5459151A (en) * 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
EP1315831B8 (en) 2000-02-24 2010-09-01 Xenon Pharmaceuticals Inc. Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents
US7232662B2 (en) 2000-09-26 2007-06-19 Xenon Pharmaceuticals Inc. Methods and compositions employing a novel stearoyl-CoA desaturase-hSCD5
JP2006518368A (ja) * 2003-02-21 2006-08-10 ファイザー・インク プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体
WO2005047253A1 (en) * 2003-11-12 2005-05-26 Lg Life Sciences Ltd. Melanocortin receptor agonists
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
EP1827438B2 (en) * 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
AR051091A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
US7829712B2 (en) * 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
US7842696B2 (en) * 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
US20110053933A1 (en) * 2008-03-26 2011-03-03 Daiichi Sankyo Company, Limited Hydroxyquinoxalinecarboxamide derivative

Also Published As

Publication number Publication date
JP2011518774A (ja) 2011-06-30
IL208232A0 (en) 2010-12-30
US8129376B2 (en) 2012-03-06
CN102036558A (zh) 2011-04-27
NZ588633A (en) 2012-03-30
CA2719000A1 (en) 2009-09-24
WO2009117676A2 (en) 2009-09-24
US20090239810A1 (en) 2009-09-24
WO2009117676A3 (en) 2010-01-07
BRPI0909183A2 (pt) 2015-08-25
ZA201007252B (en) 2011-12-28
AU2009225441A1 (en) 2009-09-24
EP2268143A2 (en) 2011-01-05
RU2010142937A (ru) 2012-04-27
MX2010010241A (es) 2010-12-06
EP2268143A4 (en) 2012-06-27
AU2009225441B2 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
KR20100134680A (ko) 스테아로일-ｃｏａ 불포화효소의 저해물질로서 신규한 피페리딘 유도체
US8039463B2 (en) Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
US20100160323A1 (en) NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
US7842696B2 (en) Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
KR100618074B1 (ko) 벤즈아미드 유도체 및 이것의 사이토킨 억제제로서 용도
JP4853965B2 (ja) アダマンタン誘導体およびアザビシクロオクタン誘導体およびアザビシクロノナン誘導体、ならびにこれらの調製方法およびｄｐｐ−ｉｖ阻害剤としてのこれらの使用
JP2002531444A (ja) ベンズアミド誘導体およびａｐｏＢ‐１００分泌阻害剤としてのそれらの使用
US8183239B2 (en) Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor
JP2003231633A (ja) 医薬組成物
CZ20011093A3 (cs) Amidové deriváty, které jsou užitečné jako inhibitory produkce cytokinů, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20101020

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20120919

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20130326

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130925

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130326

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20120919

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I